Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368853 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL30368713 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL20765392 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL20765811 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL20765806 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL20765393 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL23895451 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL20936143 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL20765691 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 | |
| SCHEMBL30368854 | 1.00 | IKZF1 (0.73) | IKZF1IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051298-B | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| EP-3672949-B9 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-04-05 | — | — | EP | claimed |
| EP-3672949-B1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | claimed |
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | claimed |
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-07-23 | — | — | US | claimed |
| EP-3672949-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-07-01 | — | — | EP | claimed |
| CN-111051298-A | 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2020-04-21 | — | — | CN | claimed |
| US-10414755-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2019-09-17 | — | — | US | claimed |
| WO-2019038717-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-28 | — | — | WO | claimed |
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| US-20230332104-A1 | ZBTB32 INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-10-19 | — | — | US | disclosed |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | NOVARTIS AG (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4183782-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DI ONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-05-24 | — | — | EP | disclosed |
| EP-4183782-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DI ONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-05-24 | — | — | EP | disclosed |
| US-10647701-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-12 | — | — | US | disclosed |
| US-10647701-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-12 | — | — | US | disclosed |
| US-10640489-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-10640489-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-10414755-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2019-09-17 | — | — | US | disclosed |
| US-10414755-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332104-A1 | ZBTB32 INHIBITORS AND USES THEREOF | IKZF2, IKZF3, BAZ2B | IKZF1 38/4885IKZF2 1/4885 |
| US-10414755-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | IKZF1 3202/4885IKZF2 4353/4885 |
| US-10640489-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | IKZF1 3202/4885IKZF2 4353/4885 |
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, H1-0, RXFP1 | IKZF1 3202/4885IKZF2 4353/4885 |
| US-10647701-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, H1-0, RXFP1 | IKZF1 3202/4885IKZF2 4353/4885 |
| US-11999802-B2 | Compositions and methods for selective protein degradation | CRBN, RPS27A, COPB1 | IKZF1 781/4885IKZF2 336/4885 |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | HAVCR2, MICA, CD74 | IKZF1 43/4885IKZF2 67/4885 |
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, H1-0, RXFP1 | IKZF1 3202/4885IKZF2 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.